MediWound shareholders approve 2026 meeting items

MediWound Ltd. reported the results of its 2026 annual general meeting of shareholders.

Rhea-AI Filing Summary

MediWound Ltd. reported the results of its 2026 annual general meeting of shareholders. A quorum of 6,208,465 ordinary shares, representing 48.3% of outstanding shares as of March 31, 2026, was present in person or by proxy. Shareholders approved all proposals, including the election of five directors, each receiving approximately 99% of votes cast. Proposal 3 was also approved by the required special majority of shareholders who were not controlling shareholders and lacked a “personal interest” under Israeli Companies Law. The report and its exhibit are incorporated by reference into MediWound’s existing Form S-8 and Form F-3 registration statements.

Key Figures

Quorum shares: 6,208,465 shares Quorum percentage: 48.3% Votes for Nachum Shamir: 6,162,008 votes (99.3%) +3 more

6 metrics

Quorum shares 6,208,465 shares Represented at 2026 annual meeting; 48.3% of outstanding as of March 31, 2026

Quorum percentage 48.3% Portion of outstanding ordinary shares present at 2026 annual meeting

Votes for Nachum Shamir 6,162,008 votes (99.3%) Director election at 2026 annual meeting, excluding abstentions

Votes for Dr. Vickie R. Driver 6,168,784 votes (99.4%) Director election at 2026 annual meeting, excluding abstentions

Proposal with 99.8% support 6,191,209 votes (99.8%) Non-director proposal approved at 2026 annual meeting, excluding abstentions

Proposal 3 special majority for 6,093,382 votes (99.5%) Non-controlling, no personal interest shareholders voting in favor of Proposal 3

Key Terms

quorum, Israeli Companies Law, controlling shareholders, personal interest, +1 more

5 terms

quorum financial

"constituting the requisite quorum, each of the following numbered proposals"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

Israeli Companies Law regulatory

"approved by the below majorities of our shareholders under the Israeli Companies Law, 5759-1999"

Israeli Companies Law is the main statute that sets the rules for forming, running and dissolving corporations in Israel, covering directors’ duties, shareholder rights, company reporting and corporate governance. Investors care because it defines who makes decisions, what information companies must share, and how disputes or transactions are handled — like the rulebook for a club that determines how members vote, get information, and protect their stake.

controlling shareholders financial

"shareholders who (i) were not controlling shareholders and (ii) lacked a “personal interest”"

personal interest regulatory

"lacked a “personal interest” (as defined under the Companies Law) voted in favor of Proposal 3"

incorporated by reference regulatory

"The contents of this Form 6-K ... are hereby incorporated by reference into the Company’s Registration Statements"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MediWound (MDWD) announce in its May 2026 Form 6-K?

MediWound reported the results of its 2026 annual shareholder meeting. All proposals were approved, including electing five directors, and the meeting had a 48.3% quorum. The Form 6-K is also incorporated into several existing S-8 and F-3 registration statements.

How many MediWound (MDWD) shares were represented at the 2026 annual meeting?

A total of 6,208,465 MediWound ordinary shares were represented at the meeting, equal to 48.3% of outstanding ordinary shares as of the March 31, 2026 record date. This level of participation satisfied the quorum requirement under Israeli Companies Law.

Which directors were elected at MediWound’s 2026 shareholder meeting?

Shareholders elected five director nominees: Nachum Shamir, Dr. Vickie R. Driver, David Fox, Shmuel (Milky) Rubinstein, and Stephen T. Wills. Each nominee received about 99% of votes cast in favor, excluding abstentions, according to the voting results disclosed.

How was Proposal 3 approved at MediWound’s 2026 meeting?

Proposal 3 received both overall shareholder approval and a required special majority. Among shareholders who were not controlling shareholders and lacked a “personal interest,” 6,093,382 votes (99.5%) were cast in favor and 33,681 (0.5%) against, excluding abstentions as required.

What were the overall voting results for MediWound’s non-director proposals?

One proposal received 6,191,209 votes in favor (99.8%), 15,232 against (0.2%), and 2,024 abstentions. Another proposal received 6,115,519 votes in favor (99.5%), 33,681 against (0.5%), and 59,265 abstentions. Each proposal was approved under Israeli Companies Law requirements.

How does this Form 6-K affect MediWound’s existing registration statements?

The Form 6-K, including Exhibit 99.1, is incorporated by reference into multiple MediWound Form S-8 and Form F-3 registration statements. This means the disclosed meeting results and related information become part of those effective registration statements on file with the SEC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 04:05 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549
______________________

FORM 6-K 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of May 2026

Commission File Number: 001-36349

MediWound Ltd. (Translation of registrant’s name into English)

42 Hayarkon Street

Yavne, 8122745 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS 

Results of 2026 Annual Shareholder Meeting

On May 6, 2026, MediWound Ltd. (“we,” “us” or the “Company”) held its 2026 annual general meeting of shareholders (the “Meeting”). At the Meeting, our shareholders voted on a few proposals, each of which is listed below and was described in more detail in our notice and proxy statement for the Meeting, which were attached as Exhibit 99.1 to a Report of Foreign Private Issuer on Form 6-K (a “Form 6-K”) that we furnished to the Securities and Exchange Commission (the “SEC”) on March 30, 2026. Each of those descriptions is incorporated by reference herein.

Based on the presence in person or by proxy at the Meeting of 6,208,465 (or 48.3%) of our outstanding ordinary shares, par value New Israeli Shekels (NIS) 0.07 per share (“ordinary shares”) as of the March 31, 2026 record date for the Meeting, constituting the requisite quorum, each of the following numbered proposals, which was presented for a vote at the Meeting, was approved by the below majorities of our shareholders under the Israeli Companies Law, 5759-1999 (the “Companies Law”) (each majority, as reflected in the percentages presented below, was determined after excluding abstentions, in accordance with the Companies Law):

(1) Re-election of each of Mr. Nachum Shamir, Dr. Vickie R. Driver, Mr. David Fox, Mr. Shmuel (Milky) Rubinstein, and Mr. Stephen T. Wills to the Company’s board of directors, or Board, to serve until the next annual general meeting of shareholders of the Company and until their respective successors are duly appointed and qualified, or until their earlier resignation or removal:

Name of Director Nominee		Votes in Favor		Votes Against		Abstentions
Nachum Shamir		6,162,008 (99.3%)		42,782 (0.7%)			3,674
Dr. Vickie R. Driver		6,168,784 (99.4%)		34,888 (0.6%)			4,793
David Fox		6,139,229 (99.0%)		64,425 (1.0%)			4,810
Shmuel (Milky) Rubinstein		6,169,440 (99.5%)		34,215 (0.5%)			4,810
Stephen T. Wills		6,149,332 (99.1%)		54,323 (0.9%)			4,810

(2) Reappointment of Somekh Chaikin, a member firm of KPMG, as the Company’s independent registered public accounting firm for the year ending December 31, 2026 and for the additional period until the next annual general meeting of shareholders of the Company, and authorization of the Board (with power of delegation to its audit committee) to fix the independent registered public accounting firm’s remuneration in accordance with the volume and nature of its services:

Votes in Favor		Votes Against		Abstentions
6,191,209 (99.8%)		15,232 (0.2%)		2,024

(3) Approval of the payment of an annual cash bonus to the Company’s Chief Executive Officer, Mr. Ofer Gonen, in respect of his performance in 2025:

Votes in Favor		Votes Against		Abstentions
6,115,519 (99.5%)		33,681(0.5%)		59,265

The vote tally on Proposal 3 also achieved the requisite special majority under the Companies Law, as a majority of shareholders (excluding abstentions) who (i) were not controlling shareholders and (ii) lacked a “personal interest” (as defined under the Companies Law) voted in favor of Proposal 3, as reflected in the below tally among those shareholders:

Votes in Favor		Votes Against
6,093,382 (99.5%)		33,681 (0.5%)

Incorporation by Reference

The contents of this Form 6-K (including the information contained in Exhibit 99.1) are hereby incorporated by reference into the Company’s Registration Statements on (i) Form S-8, filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 5, 2021, August 9, 2022, August 15, 2023, March 19, 2025 and March 5, 2026 (Registration Nos. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, 333-266697, 333-273997, 333-285897, and 333-294055, respectively), and (ii) Form F-3, filed with the SEC on August 29, 2024 and March 19, 2025 (Registration Nos. 333-281843 and 333-285908, respectively).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 6, 2026 MEDIWOUND LTD.   By: /s/ Hani Luxenburg Name: Hani Luxenburg Title: Chief Financial Officer